Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Stock Information for Chimerix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chimerix Inc.

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq - TURN)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.